Serimmune
Biotechnology company focused on mapping human immunity through its SERA (Serum Epitope Repertoire Analysis) platform, which comprehensively profiles the antibody response to infections, vaccines, and autoimmune conditions.
Notes
Serimmune is a biotechnology company focused on mapping human immunity through advanced antibody profiling technologies. The company is headquartered in Santa Barbara, California.
The company's proprietary SERA (Serum Epitope Repertoire Analysis) platform enables comprehensive profiling of the antibody response in human serum. This technology can identify the specific epitopes (antibody binding sites) that the immune system is responding to, providing deep insights into:
- Infectious disease responses
- Vaccine efficacy
- Autoimmune conditions
- Cancer immunology
Serimmune's technology has applications in diagnostics, vaccine development, and therapeutic discovery.
Team
- Noah Nasser - Chief Executive Officer
- John Shon, Ph.D. - Co-founder & Chief Scientific Officer
Additional Research Findings
- SERA platform for antibody profiling
- Serum Epitope Repertoire Analysis technology
- Applications in infectious disease, vaccines, autoimmunity
- Santa Barbara, California headquarters
- Founded in 2016
- Immune mapping and diagnostics focus
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |